Program Growth Brings No-Cost Myopia Management to More Under-Resourced Children
ROCHESTER, N.Y., June 23, 2025—CooperVision’s Generation Sight initiative continues to grow and make an impact, bridging disparities in myopia management access among under-resourced children in the U.S. In its first year, the program has delivered life-changing care to children in Boston and Chicago, with recent expansion into additional community health centers throughout the greater Boston area and into Rhode Island. Participating centers delivering this standard of care now include Charles River Community Health, The Dimock Center, DotHouse Health, Lynn Community Health Center, Providence Community Health Centers, and South Boston Community Health Center.
“The expansion of Generation Sight is twofold: it brings much-needed myopia treatment to children who might not otherwise have access, and it offers students and residents invaluable real-world experience with contact lenses,” said Michele Andrews, OD, Vice President, Marketing and Professional Affairs, Americas, CooperVision. “This experience, which includes hands-on training, helps them prepare to meet the needs of a broader range of patients after graduation.”
Generation Sight was developed in partnership with the Illinois College of Optometry (ICO), Massachusetts College of Pharmacy and Health Sciences (MCPHS), and New England College of Optometry (NECO). The program connects families who may not otherwise receive myopia care with treatment through collaborations involving optometry school faculty, residents, and students. These professionals help identify and serve children in need while engaging multidisciplinary community partners to extend the program’s reach.
The initiative offers MiSight® 1 day* soft contact lenses for age-appropriate children and Paragon CRT® orthokeratology† lenses at no cost for as long as participating patients require treatment for their myopia. The momentum in this program comes at a time when myopia is on the rise globally. Currently affecting 2.6 billion people worldwide, it is estimated that nearly 5 billion people, or half of the world population, will have myopia by 2050.1
“Programs like Generation Sight are vital in addressing this growing public health concern, particularly in communities where access to eye care is limited. By combining clinical innovation, academic partnerships, and community outreach, CooperVision is creating a scalable model for improving children’s eye health nationwide,” said Dr. Andrews.
For more information about CooperVision, visit www.coopervision.com.
###
* Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
† U.S. Indications for Use: Rigid Gas Permeable Paragon CRT® Contact Lenses (paflufocon B), Paragon CRT® 100 Contact Lenses (paflufocon D) for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in non-diseased eyes. The lenses are indicated for overnight wear in a Corneal Refractive Therapy fitting program for the temporary reduction of myopia up to 6.00 diopters in eyes with astigmatism up to 1.75 diopters. The lenses may be disinfected using only a chemical disinfection system
1 Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042. doi:10.1016/j.ophtha.2016.01.006.
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 16,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Media Contact
Laura DiCaprio, Associate Director
McDougall Communications for CooperVision
Laura@mcdougallpr.com or +1-585-434-2153
18181 06/25